Skip to content

Trial Summary

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 358 patients wi

Acronym:

INTRIGUE

ACTRN/NCT /ethics:

NCT03673501

Scientific title:

A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Sponsor / Cooperative group:

Deciphera

Trial & Patient Characteristics

Cancer TypeBowel and colon
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2019-02-11
Anticipated End Date2022-03-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Sarwan Bishnoi
Recruitment StatusRecruiting